Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Anna Amela Valsecchi"'
Autor:
Anna Amela Valsecchi, Filippo Giovanardi, Francesco Malandrini, Michela Meregaglia, Alberto Servetto, Chiara Bennati, Carmine Pinto, Massimo Di Maio, Oriana Ciani
Publikováno v:
Breast, Vol 78, Iss , Pp 103817- (2024)
Background: Inclusion of patient-reported outcomes (PROs) in oncology clinical trials is strongly recommended. However, selecting the most appropriate patient-reported outcome measures (PROMs) is not easy. This study aimed to develop a breast cancer
Externí odkaz:
https://doaj.org/article/37033068ba08440294db2b5dd2fcb9b0
Autor:
Gaia Giannone, Daniele Castaldo, Valentina Tuninetti, Giulia Scotto, Margherita Turinetto, Anna Amela Valsecchi, Michele Bartoletti, Serafina Mammoliti, Grazia Artioli, Giorgia Mangili, Vanda Salutari, Domenica Lorusso, Gennaro Cormio, Claudio Zamagni, Antonella Savarese, Massimo Di Maio, Graziana Ronzino, Carmela Pisano, Sandro Pignata, Giorgio Valabrega
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundEndometrial cancer (EC) therapeutic and diagnostic approaches have been changed by the development of a new prognostic molecular classification, the introduction of dostarlimab in microsatellite instability (MSI) high pre-treated advanced E
Externí odkaz:
https://doaj.org/article/b9a686d498904e73bedff9d6707f8bb3
Autor:
Anna Amela Valsecchi, Jessica Paparo, Valeria Pirro, Matteo Manfredi, Massimo Di Maio, Rossana Dionisio
Publikováno v:
Tumori.
Introduction: The achievement of complete response with chemotherapy after multiple treatment lines in metastatic breast cancer and the chemosensitivity in a luminal-like breast cancer are two important issues as it is often asked whether there is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4c9d15ff733e770bd3cc6bd641329c2
https://pubmed.ncbi.nlm.nih.gov/36482741
https://pubmed.ncbi.nlm.nih.gov/36482741
Autor:
Anna Amela Valsecchi, Rossana Dionisio, Olimpia Panepinto, Jessica Paparo, Andrea Palicelli, Francesca Vignani, Massimo Di Maio
Publikováno v:
Cancers. 15:2435
In prostate cancer (PC), the presence of BRCA somatic and/or germline mutation provides prognostic and predictive information. Meta-analysis aims to estimate the frequency of BRCA mutations in patients with PC (PCp). In November 2022, we reviewed lit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2586dd6552411392c4b04ee4aa6df356
https://doi.org/10.3390/cancers15092435
https://doi.org/10.3390/cancers15092435
Autor:
Lucia Musacchio, Anna Amela Valsecchi, Vanda Salutari, Giorgio Valabrega, Floriana Camarda, Valentina Tuninetti, Gaia Giannone, Michele Bartoletti, Claudia Marchetti, Sandro Pignata, Anna Fagotti, Giovanni Scambia, Massimo Di Maio, Domenica Lorusso
Low grade serous carcinoma of the ovary and peritoneum (LGSC) is characterized by low response rates to chemotherapy and by MAPK pathway alterations. Phase II/III clinical trials tested different MEK inhibitors (MEKis) in this complex malignancy, wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f3ff6a9a9b17d9086e37f3dec54d9ba
https://hdl.handle.net/10807/219720
https://hdl.handle.net/10807/219720
